The U.S. IPO market continues to generate mixed reviews for biotech this year. As the 16th and 17th IPOs to price on Nasdaq, Colucid Pharmaceuticals Inc. and Adaptimmune Ltd. offered diverging stories, though neither wowed on the first trading day Wednesday.